1 R) from human immunodeficiency virus type 1 (HIV-I) RNA is presented using recently introduced NMR me

2 sera displayed neutralizing activity against HIV-I/MN and HIV-I/3B viral strains.

3  of the DNA polymerase I Klenow fragment and HIV I reverse transcriptase.

4 neoplasia and may have relevance to KSHV and HIV-I interactions.

5 d neutralizing activity against HIV-I/MN and HIV-I/3B viral strains.

6 t showed the most significant dysregulation, HIV-I NEF, was validated at both the transcript level an

7 s-activation response element (TAR) RNA from HIV-I.

8                  HOC with NH2-terminal fused HIV-I CD4 receptor of 183 amino acids can be detected on

9 hin the human immunodeficiency virus type I (HIV-I) 5'-untranslated region (UTR) containing the dimer

10 ing the human immunodeficiency virus type I (HIV-I) envelope protein gp160 in mammalian cells.

11 adicate human immunodeficiency virus type I (HIV-I) infection.

12 ture of human immunodeficiency virus type I (HIV-I) preintegration complexes.

13                              Dimerization of HIV-I protease (HIV PR) monomers is an essential prerequ

14 ranspositional enhancements near each end of HIV-I.

15            The end regions of preintegrative HIV-I apparently form a unique nucleoprotein structure,

16 using the gene expression signature from the HIV-I NEF pathway verified the accuracy of our method.

17 required to form the native structure of the HIV-I intasome in infected cells.

18 nthesis of the sulfondiimine analogue of the HIV-I reverse transcriptase-inhibitor L-737,126.

19 ffectively promotes recombination within the HIV-I 5'-UTR.

20 es categorized according to the INNO-LIA(TM) HIV I/II, the gold standard confirmatory assay.

21 ), 0.9 muM), and it showed moderate in vitro HIV I inhibition.

22 rresponding to conserved target sites within HIV-I cDNA.